US concerns grow over China's rapid biotech industry expansion

Source:SCMP

02 — Who / Subject

Chinese biotech companies, US government

03 — Where / Locus

China, United States

04 — When / Temporality

June 2, 2026

Verified: June 2, 2026

05 — Why / Core Summary

"Chinese biotech firms recorded $60 billion in cross-border licensing deals in Q1 2026. US policymakers are concerned that capital flow into Chinese biotech is fueling China's pharmaceutical value chain ascent. Tensions are rising as the US considers tighter controls on the sector."

Conflict Analysis

This reflects the ongoing geopolitical rivalry extending into the critical technology and healthcare sectors, with potential implications for global pharmaceutical supply chains.

Recommended Background Resource

Affiliate / AdAI Curation

The Kill Chain: Defending America in the Future of High-Tech Warfare

Author: Christian Brose

This book provides a critical perspective on how technological dominance, including biotechnology and AI, is central to the strategic competition between the US and China, explaining why the US views China's industrial advancement as a national security threat.

Explore Background Book (Amazon)

As an Amazon Associate, COMPAMIR earns from qualifying purchases.

Post